Molecular Cloning and Characterization of a cDNA Encoding the Third Putative Mammalian Hyaluronan Synthase*

(Received for publication, January 28, 1997, and in revised form, February 12, 1997)

Andrew P. Spicer Dagger , Jeffrey S. Olson and John A. McDonald Dagger

From the Department of Biochemistry and Molecular Biology, Mayo Clinic Scottsdale, Scottsdale, Arizona 85259

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES


ABSTRACT

We report the isolation of a cDNA encoding the third putative hyaluronan synthase, HAS3. Partial cDNAs and genomic fragments of mouse Has3 were obtained using a degenerate polymerase chain reaction approach. Partial clones facilitated the isolation of genomic and cDNA clones representing the mouse Has3 open reading frame. The open reading frame of 554 amino acids predicted a protein of 63.3 kDa with multiple transmembrane domains and several consensus HA binding motifs. Sequence comparisons indicated that mouse Has3 is most closely related to Has2 (71% amino acid identity) and also related to Has1 (57% identity), Xenopus laevis DG42 (56% identity), and Streptococcus pyogenes HasA (28% identity). Isolation of a genomic fragment of human HAS3 indicated high conservation between mouse and human sequences, similar to those observed for HAS1 and HAS2. Expression of the mouse Has3 open reading frame in transfected COS-1 cells led to high levels of hyaluronan synthesis, as determined through a classical particle exclusion assay, and by in vitro HA synthase assays. These results suggest that there are three putative mammalian hyaluronan synthases encoded by three separate but related genes which comprise a mammalian hyaluronan synthase (HAS) gene family.


INTRODUCTION

Hyaluronan (HA)1 is a linear unbranched glycosaminoglycan (GAG) composed of repeating disaccharide units of D-glucuronic acid(beta 1right-arrow3)N-acetylglucosamine(beta 1right-arrow4). HA is a major constituent of the extracellular matrix of most tissues and organs, especially during embryonic development, where it has been proposed to play important roles in cell migration, proliferation, and the development of tissue architecture (1-3). In addition, HA has been implicated in tumorigenesis, and defects in HA metabolism are a hallmark of several important diseases including rheumatoid arthritis, Grave's ophthalmopathy, cirrhosis of the liver, and accelerated aging in Werner's syndrome (1-4). Unlike other GAGs, which are synthesized within the Golgi network and attached to protein, HA is synthesized at the inner face of the plasma membrane and is subsequently extruded to the outside of the cell (5, 6). Recently, we and others (7-11) have identified two mammalian genes, HAS1 and HAS2, encoding putative plasma membrane HA synthases related to the Streptococcus pyogenes HA synthase, HasA. Expression of either HAS1 or HAS2 by cells led to high levels of HA biosynthesis, consistent with both proteins playing critical roles in HA biosynthesis, possibly as the HA synthases themselves.

While attempting to isolate fragments of the human HAS2 gene using a degenerate PCR approach, we isolated fragments of an additional related gene in the mouse and human. We now report the molecular cloning and characterization of a cDNA encoding the third putative mammalian hyaluronan synthase, HAS3.


EXPERIMENTAL PROCEDURES

cDNA and Genomic Cloning and Expression

Previously described degenerate oligonucleotide primer pools (10), DEG 1 and DEG 5, were utilized in an attempt to amplify fragments of HAS genes from human and mouse genomic DNA. PCR buffer conditions were as recommended by the manufacturer (Boehringer Mannheim). The templates were 100 ng of human T47D mammary carcinoma cell line genomic DNA and 100 ng of mouse 129Sv/J genomic DNA, prepared by standard procedures. Cycling parameters were as follows: 35 cycles of 94 °C for 10 s, 50 °C for 30 s, and 72 °C for 1 min, followed by a final extension step at 72 °C for 10 min. Amplified fragments of the expected size were identified through agarose gel electrophoresis, gel-purified, and cloned directly as described previously (10). Two additional degenerate oligonucleotide primer pools (DEG 10 and DEG 11) were designed, based upon the conserved amino acid sequences GWGTSGRK and RWLNQQTRW (Ref. 10 and Fig. 2). Similar PCR conditions were used to amplify fragments of the expected size from human and mouse genomic DNA using these primers.


Fig. 2. Comparison of mouse Has3 with related enzymes. A, amino acid alignment of mouse Has3 with mouse Has2 (MHas2), mouse Has1 (MHas1), Xenopus laevis DG42 (DG42), and S. pyogenes HasA. Conserved residues are boxed. Gaps have been introduced to maximize the alignment. Asterisks indicate positions at which there have been significant conservative amino acid substitutions. B, alignment of two regions of the mouse Has3 protein sequence with equivalent areas of related glycosyltransferases, mouse Has2, mouse Has1, Xenopus DG42, S. pyogenes HasA, R. meliloti NodC, Gossypium hirsutum putative cellulose synthase A1 (celA1), and S. cerevisiae chitin synthase 2 (Chs2). Site-directed mutagenesis of the residues highlighted in bold of yeast Chs2 resulted in loss of enzymatic activity (18), suggesting that these residues may be critical for beta 1right-arrow4 glycosyltransferase activity. C, Kyte-Doolittle hydrophilicity plots of mouse Has3, mouse Has2, mouse Has1, and S. pyogenes HasA. Hydrophobic areas are represented below the axes. Potential transmembrane domains are indicated by black bars drawn below each plot.
[View Larger Version of this Image (84K GIF file)]


Based upon the sequence of partial fragments obtained as described above, a single pair of oligonucleotide primers, forward 5'-TAC TGG ATG GCT TTC AAC GTG GAG-3' (corresponding to nucleotides 790-813, Fig. 1B) and reverse 5'-GTC ATC CAG AGG TGG TGC TTA TGG-3' (corresponding to antisense complement of nucleotides 1142-1119, Fig. 1B), was designed to facilitate PCR screening of a mouse 129Sv P1 genomic library (Genome Systems, St. Louis, MO). Three positive P1 clones were obtained, and restriction fragments spanning the entire mouse Has3 gene were identified and subcloned into pBluescript (Stratagene, La Jolla, CA) based vectors using standard procedures. Sequence analyses, using synthetic oligonucleotides made to the mouse Has3 sequence and to vector sequence, permitted the identification of the predicted mouse Has3 open reading frame (ORF), based upon comparison with mouse Has1 and Has2 sequences (7, 10) and genomic structures.2 All sequences were determined from both DNA strands from multiple overlapping sequencing runs.


Fig. 1.

Nucleotide, amino acid sequence, and embryonic expression of hyaluronan synthase 3. A, amino acid alignment of a partial sequence for human HAS3 with the equivalent area of mouse Has3. Conserved amino acids are indicated by a dash (---). B, nucleotide and predicted amino acid sequence of the mouse Has3 open reading frame as derived from cDNA and genomic clones. Sequences representing consensus HA binding motifs are underlined. The location of three introns within the gene are indicated by arrowheads. The first intron is located immediately preceding the start codon (ATG). The partial human HAS3 sequence and the mouse Has3 ORF sequence described herein have been deposited in GenBankTM and are available through accession numbers U86409[GenBank] and U86408[GenBank], respectively. C, Northern blot depicting the expression of mouse Has3 at four stages of mouse embryonic development. A cDNA probe representing the mouse Has3 ORF was radiolabeled and hybridized to a blot containing mouse embryonic poly(A)+ RNAs (CLONTECH) under conditions recommended by the manufacturer. Two transcripts, a major transcript of approximately 6.0-6.5 kb and a minor transcript of approximately 4.0 kb, were observed. Mouse Has3 expression appears to be highest in the late gestation embryo (17.5 days postcoitum).


[View Larger Version of this Image (37K GIF file)]


The sequence obtained from analysis of genomic clones was confirmed from cDNA sequence through the reverse transcriptase-polymerase chain reaction amplification, cloning, and sequencing of a mouse Has3 ORF cDNA from late gestation (17.5 days postcoitum) mouse C57BL/6J embryo total RNA. Oligonucleotides possessed EcoRI restriction endonuclease sites (underlined) at their 5' termini to facilitate subsequent cloning steps and had the following sequence: forward, 5'-CCAAG ATG GCG GTG CAG CTG ACT ACA GCC-3', corresponding to nucleotides 1-24, Fig. 1B) and reverse, 5'-CC TCA CAC CTC CGC AAA AGC CAG GC-3', corresponding to the antisense complement of nucleotides 1665-1643, Fig. 1B). First-strand cDNA synthesis was performed as described (10) using the mouse Has3 reverse oligonucleotide primer. First-strand cDNAs were PCR-amplified using standard PCR buffer conditions supplemented with 2% deionized formamide, through 35 cycles of 94 °C for 10 s, 65 °C for 30 s, and 72 °C for 2 min, followed by a final extension step of 72 °C for 10 min. Amplified cDNAs of the expected size were gel-purified and cloned as described previously. All sequence analyses were performed using the Genetics Computer Group (GCG) package and MacVector programs.

To determine the temporal expression pattern in the developing mouse embryo, the mouse Has3 ORF cDNA was labeled with [alpha 32P]dCTP by random priming (12) and hybridized to a Northern blot of mouse embryo messenger RNA (CLONTECH, Palo Alto, CA) under conditions recommended by the manufacturer.

Transfections, HA Coat, and HA Synthase Assays

The mouse Has3 ORF, amplified and cloned as described above, was cloned into the EcoRI site of the expression vector pCIneo (Promega, Madison, WI). The mouse Has3 expression vector was co-transfected with a pCMVbeta -gal vector into COS-1 (SV40-transformed African green monkey kidney) cells using LipofectAMINETM (Life Technologies Inc.) according to the manufacturer's instructions. Positive control transfections utilized the mouse Has2 expression vector previously described (10). HA coat assays (13) and detection of beta -galactosidase activity were performed as described (10).

Crude cell membrane preparations were isolated from COS-1 cells transfected with the mouse Has3 expression vector, the mouse Has2 expression vector (10), and the pCIneo vector (control), essentially as described (14), except the final membrane pellets were resuspended in 50 µl of lysis buffer (LB) consisting of 10 mM KCl, 1.5 mM MgCl2, and 10 mM Tris-HCl, pH 7.4, plus protease inhibitors (aprotinin, leupeptin, and phenylmethylsulfonyl fluoride) (LB+). Protein content of crude membrane preparations was determined by a BCA assay (Pierce). To detect HA synthase activity, duplicate samples of approximately 100 µg of crude membrane protein were incubated overnight at 37 °C in a total reaction volume of 200 µl under the following conditions: 5 mM dithiothreitol, 15 mM MgCl2, 25 mM HEPES, pH 7.1, 1 mM UDP-GlcNAc, 0.05 mM UDP-GlcUA, 0.4 µg of aprotinin, 0.4 µg of leupeptin, 0.5 µCi of UDP-[14C]GlcUA (ICN, Costa Mesa, CA). An additional specificity control reaction was set up in which UDP-GlcNAc was omitted. After overnight incubation, samples were boiled for 10 min and subsequently divided in two. Streptomyces hyaluronidase (1 turbidity reducing unit) was added to one half and incubated for an additional hour at 37 °C. SDS was added to a final concentration of 1%, and samples were boiled and analyzed by descending paper chromatography essentially as described (15).


RESULTS

While cloning fragments of human HAS2, we isolated a fragment of an additional gene that was related to but distinct from human HAS1 and HAS2. We isolated this fragment through PCR amplification with previously described HAS-specific degenerate oligonucleotide primers DEG 1 and DEG 5 (10). In contrast to our previous studies in which we amplified off a cDNA template, in this instance we used a genomic DNA template. HAS fragments were amplified from human and mouse genomic DNA. Subsequent cloning and sequence analyses revealed that all the human and mouse clones fell into two categories. The first category represented clones of human and mouse HAS2, while the second category of clones were highly conserved between human and mouse, and represented fragments derived from a related gene that was not HAS1 or HAS2. Subsequently, we used additional combinations of degenerate primers to amplify and clone additional fragments of this novel gene, which we have designated HAS3 in humans and Has3 in the mouse (Fig. 1A). Alignment of the partial sequence of human HAS3 and mouse Has3 indicated a very high level of sequence conservation (99%) (Fig. 1A). This is similar to the high level of conservation observed for human and mouse HAS1 (96%) and HAS2 (99%) (7-11).

Through genomic cloning and sequence analyses and confirmation of this sequence from cDNA-derived clones, we identified an ORF of 1662 base pairs for mouse Has3 (Fig. 1B). This ORF encodes a polypeptide of 554 amino acids with a predicted molecular mass of 63.3 kDa. This polypeptide is only 2 amino acids longer than the mouse Has2 polypeptide (10). Sequence alignments indicated that mouse Has3 is 71, 57, 56, and 28% identical to mouse Has2 (10), mouse Has1 (HAS protein) (7), Xenopus DG42 (16), and S. pyogenes HasA (17), respectively (Fig. 2A). Like Has1 and Has2, residues demonstrated to be critical for N-acetylglucosaminyltransferase activity of yeast chitin synthase 2 (18) are completely conserved. In addition, these residues are conserved with members of a recently identified putative plant cellulose synthase family (19) (Fig. 2B).

Hydrophilicity plots suggested that Has3 is very similar in structure to Has2 and Has1 and predicted the presence of multiple transmembrane domains, with two at the N terminus and a cluster at the C terminus (Fig. 2C). Significantly, like Has2 and Has1, the Has3 sequence predicts the presence of several potential HA binding motifs defined by the consensus B(X7)B (20) (underlined in Fig. 1B). Furthermore, these motifs are located at similar positions within the Has3 polypeptide.

In contrast to mouse Has2, which is highly expressed from as early as day 7.5 postcoitum through late gestation in the developing mouse embryo (10), mouse Has3 is expressed predominantly in the late gestation embryo (Fig. 1C). One major transcript of approximately 6.0-6.5 kb and a minor transcript of approximately 4.0 kb were observed (Fig. 1C).

To test the enzyme activity of mouse Has3, we transfected an expression vector carrying the Has3 ORF into COS-1 cells. We tested mouse Has3 alongside mouse Has2 and a negative control of vector alone. Expression of mouse Has3 by COS-1 cells led to the generation of well pronounced HA-dependent pericellular coats, as previously observed for Has2 (10) (Fig. 3). To confirm the HA biosynthetic capability of Has3-transfected cells, we performed HA synthase assays on crude membranes prepared from these cells. These assays indicated that crude membranes prepared from either Has3- or Has2-transfected COS-1 cells were capable of converting UDP-[14C]GlcUA into significant amounts of a high molecular weight product only in the presence of UDP-GlcNAc (Table I). Furthermore, this product could be specifically degraded by Streptomyces hyaluronidase (Table I). Thus, in COS-1 cells, Has2 and Has3 appear to possess similar enzymatic activities and are therefore likely to represent bona fide mammalian HA synthases.


Fig. 3. Mouse Has3-transfected COS-1 cells generate HA-dependent pericellular coats. COS-1 cells were transfected with mouse Has2 pCIneo (A), pCIneo (B), and mouse Has3 pCIneo (C-F) vectors. Addition of fixed horse erythrocytes to culture dishes permitted the visualization of pericellular coats. Pericellular coats were produced by mouse Has2-transfected cells (A) as described previously (10) and by mouse Has3-transfected cells (C and E). pCIneo (vector only control) transfected cells failed to produce coats (B). Mouse Has3-transfected cells produced pericellular coats that were destroyed by treatment with a specific hyaluronidase from Streptomyces (5 turbidity reducing units/ml for 1 h at 37 °C) (compare panels E, before hyaluronidase treatment, and F, after hyaluronidase treatment). In contrast, pericellular coats remained on mock hyaluronidase-treated cells (compare panels C, before, and D, after mock hyaluronidase treatment).
[View Larger Version of this Image (148K GIF file)]


Table I.

Hyaluronan synthase activity of transfected COS-1 cells


Vector + UDP-GlcNAca  - UDP-GlcNAc Hyaluronidaseb

Mouse Has3 pCIneo 204.2c 1.9d  -
65.0 2.2 +
Mouse Has2 pCIneo 26.9 2.5  -
10.5 2.0 +
pCIneo (control) 11.0 NDe  -
10.3 ND +

a Plus and minus symbols indicate whether or not UDP-GlcNAc was included in these reactions.
b Plus and minus symbols indicate whether or not a reaction was subsequently treated for 1 h at 37 °C with 1 TRU Streptomyces hyaluronidase prior to paper chromatography.
c Numbers represent picomoles of radiolabeled product formed and were calculated taking into account the specific activity of the UDP-[14C]GlcUA used, the amount of cold UDP-GlcUA per reaction, and assumed a scintillation counting efficiency of >95%. Based upon these calculations, 1 pmol of radiolabeled product is represented by 384 dpm, i.e. 204.2 pmol of product was calculated from 78,413 dpm. Numbers represent the mean calculated from duplicate reactions.
d Number represents the result of a single reaction in each instance.
e Not determined.


DISCUSSION

Three mammalian putative hyaluronan synthases, HAS1, HAS2, and HAS3, have now been identified. The three proteins are encoded by three separate but related genes, which constitute a mammalian HAS gene family. Sequence comparisons and structural predictions suggest that the mammalian HAS proteins are very similar in structure. They are predicted to have one or two N-terminal transmembrane domains and a cluster of C-terminal transmembrane domains separated by a large cytoplasmic loop. This topology is extraordinarily similar to that predicted for the bacterial HA synthase, HasA (21), and to that recently reported for the Rhizobium meliloti nodulation factor, NodC (22). In addition, the mammalian HAS sequences, the Xenopus DG42 sequence, HasA sequence, NodC sequence, and the recently reported putative plant cellulose synthases share critical residues shown to be required for N-acetylglucosaminyltransferase activity of yeast chitin synthase 2, making it highly likely that all these proteins are functionally related processive beta -glycosyltransferases. It has been suggested that three similar regions containing highly conserved aspartate (Asp) residues will be present in all such processive glycosyltransferases ((23) and Fig. 2B). These highly conserved residues may represent sites such as cation binding sites that in turn may coordinate nucleotide-sugar interaction with the enzyme.

Semino et al. (24) have postulated that DG42 and its related mammalian homologues, rather than being bona fide HA synthases, may stimulate HA production through synthesizing chitin oligosaccharide primers, which are required and rate-limiting for eukaryotic HA biosynthesis. However, cell membranes isolated from bakers' yeast, Saccharomyces cerevisiae, engineered to express DG42 have HA synthesis activity in vitro when supplied with the required UDP precursors (25). This is highly significant as S. cerevisiae is deficient in UDP-glucuronic acid production and is thus incapable of HA biosynthesis. This result and ours suggest that DG42 and its related mammalian counterparts are bona fide eukaryotic hyaluronan synthases. Clearly, however, this is an area that must be thoroughly examined in future experiments by, for instance, purifying the enzyme activities.

Expression of any one of the mammalian HAS proteins in transfected mammalian cells leads to a dramatic increase in HA biosynthesis. This would suggest that the proteins have similar activities. However, the high degree of sequence conservation (96-99% identity) between human and mouse HA synthases contrasts with the lower level of identity between synthases within a species (Has1/Has2, 55% identity; Has1/Has3, 57% identity; Has2/Has3, 71% identity), arguing for evolutionary conservation of functionally important residues and for some differences in the mode of action of the three proteins. Potential differences in function of the proteins could relate to the length of the HA chain synthesized, the rate of HA synthesis, the ability to interact with cell-type specific accessory proteins, and whether or not the HA is preferentially secreted by the cell or alternatively retained by the cell in the form of a pericellular coat.

In conclusion, a small gene family encoding putative plasma membrane hyaluronan synthases is present in mammals. We have recently determined that the mouse and human HAS genes are localized on three separate autosomes (26). Our data suggest that a primitive ancestral HA synthase gene duplicated comparatively early in vertebrate evolution, and that the HAS genes have subsequently diverged with respect to the regulatory sequences controlling their expression and possibly with respect to their mode of action. This in turn would suggest that HA biosynthesis is regulated at many levels within the vertebrate organism.


FOOTNOTES

*   This work was supported by individual National Research Service Award (NRSA) 1 F32 HL09311-01 (to A. P. S.), by American Heart Association Arizona Affiliate Beginning Grant-in-aid Fellowship AZGB-19-96 (to A. P. S.), and by funds from the Mayo Foundation for Education and Research.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) U86408[GenBank] (mouse Has3) and U86409[GenBank] (human HAS3).


Dagger    To whom correspondence may be addressed: Dept. of Biochemistry and Molecular Biology, Mayo Clinic Scottsdale, 13400 East Shea Blvd., Scottsdale, AZ 85259. Tel.: 602-301-8859; Fax: 602-301-7017; E-mail: spicer{at}mayo.edu or mcdonald{at}mayo.edu.
1   The abbreviations used are: HA, hyaluronan; GAG, glycosaminoglycan; HAS, hyaluronan synthase; HAS1, hyaluronan synthase 1; HAS2, hyaluronan synthase 2; HAS3, hyaluronan synthase 3; PCR, polymerase chain reaction; ORF, open reading frame; kb, kilobase(s).
2   A. P. Spicer, J. S. Olson, and J. A. McDonald, manuscript in preparation.

ACKNOWLEDGEMENTS

We acknowledge Jill Martin within the Molecular Biology Core Facility at Mayo Clinic Scottsdale for her oligonucleotide synthesis and the graphical expertise of Marv Ruona. We also acknowledge all members of the McDonald Laboratory, Mayo Clinic Scottsdale for helpful discussions and support.


REFERENCES

  1. Laurent, T. C., and Fraser, J. R. E. (1992) FASEB J. 6, 2397-2404 [Abstract/Free Full Text]
  2. Knudson, C. B., and Knudson, W. (1993) FASEB J. 7, 1233-1241 [Abstract/Free Full Text]
  3. Toole, B. P. (1991) in Cell Biology of Extracellular Matrix (Hay, E. D., ed), pp. 305-341, Plenum Press, New York
  4. Sherman, L., Sleeman, J., Herrlich, P., and Ponta, H. (1994) Curr. Opin. Cell Biol. 6, 726-733 [Medline] [Order article via Infotrieve]
  5. Prehm, P. (1984) Biochem. J. 220, 597-600 [Medline] [Order article via Infotrieve]
  6. Philipson, L. H., and Schwartz, N. B. (1984) J. Biol. Chem. 259, 5017-1023 [Abstract/Free Full Text]
  7. Itano, N., and Kimata, K. (1996) J. Biol. Chem. 271, 9875-9878 [Abstract/Free Full Text]
  8. Itano, N., and Kimata, K. (1996) Biochem. Biophys. Res. Commun. 222, 816-820 [CrossRef][Medline] [Order article via Infotrieve]
  9. Shyjan, A. M., Heldin, P., Butcher, E. C., Yoshino, T., and Briskin, M. J. (1996) J. Biol. Chem. 271, 23395-23399 [Abstract/Free Full Text]
  10. Spicer, A. P., Augustine, M. L., and McDonald, J. A. (1996) J. Biol. Chem. 271, 23400-23406 [Abstract/Free Full Text]
  11. Watanabe, K., and Yamaguchi, Y. (1996) J. Biol. Chem. 271, 22945-22948 [Abstract/Free Full Text]
  12. Feinberg, A. P., and Vogelstein, B. (1984) Anal. Biochem. 132, 6-13
  13. Clarris, B. J., and Fraser, J. R. E. (1968) Exp. Cell Res. 49, 181-193 [Medline] [Order article via Infotrieve]
  14. Becq, F., Jensen, T. J., Chang, X. B., Savoia, A., Rommens, J. M., Tsui, L. C., Buchwald, M., Riordan, J. R., and Hanrahan, J. W. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 9160-9164 [Abstract/Free Full Text]
  15. DeAngelis, P. L., and Weigel, P. H. (1994) Biochemistry 33, 9033-9039 [Medline] [Order article via Infotrieve]
  16. Rosa, F., Sargent, T. D., Rebbert, M. L., Michaels, G. S., Jamrich, M., Grunz, H., Jonas, E., Winkles, J. A., and Dawid, I. B. (1988) Dev. Biol. 129, 114-123 [Medline] [Order article via Infotrieve]
  17. DeAngelis, P. L., Papaconstantinou, J., and Weigel, P. H. (1993) J. Biol. Chem. 268, 19181-19184 [Abstract/Free Full Text]
  18. Nagahashi, S., Sudoh, M., Ono, N., Sawada, R., Yamaguchi, E., Uchida, Y., Mio, T., Takagi, M., Arisawa, M., and Yamada-Okabe, H. (1995) J. Biol. Chem. 270, 13961-13967 [Abstract/Free Full Text]
  19. Pear, J. R., Kawagoe, Y., Schreckengost, W. E., Delmer, D. P., and Stalker, D. M. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 12637-12642 [Abstract/Free Full Text]
  20. Yang, B., Yang, B. J., Savani, R. C., and Turley, E. A. (1994) EMBO J. 13, 286-296 [Abstract]
  21. Heldermon, C., Tlapak-Simmons, V., DeAngelis, P., and Weigel, P. (1996) Glycobiology 6, 741
  22. Barny, M. A., Schoonejans, E., Economou, A., Johnston, A. W., and Downie, J. A. (1996) Mol. Microbiol. 19, 443-453 [Medline] [Order article via Infotrieve]
  23. Saxena, I. M., Brown, R. M., Jr, Fevre, M., Geremia, R. A., and Henrissat, B. (1995) J. Bacteriol. 177, 1419-1424 [Free Full Text]
  24. Semino, C. E., Specht, C. A., Raimondi, A., and Robbins, P. W. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 4548-4553 [Abstract/Free Full Text]
  25. DeAngelis, P. L., and Achyuthan, A. M. (1996) J. Biol. Chem. 271, 23657-23660 [Abstract/Free Full Text]
  26. Spicer, A. P., Seldin, M. F., Olsen, A. S., Brown, N., Wells, D. E., Doggett, N. A., Itano, N., Kimata, K., Inazawa, J., and McDonald, J. A. (1997) Genomics, in press

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.